Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.

Abstract and Introduction Review of Normal Platelet Physiology and Megakaryocytopoisis Qualitative Platelet Abnormalities Conclusion References Nitric oxide (NO) is another drug used in the neonatal ...

ATLANTA — The use of high-throughput sequencing approaches successfully identified blood and platelet disorder genes among patients with inherited, undiagnosed platelet or coagulation defects, ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...

Chronic graft versus host disease (cGVHD) is a major late complication occurring in 25–80% of allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients. 1 It is a systemic disorder ...

Blood disorders are conditions that impact the blood’s ability to function correctly. Symptoms depend on the type of blood disorder. However, some common symptoms include unexplained fatigue and ...

A simple blood test for platelet activity at middle age could one day help identify people at risk for Alzheimer’s disease decades ahead of time, allowing for possible preventive therapy. The ...

The pathogenesis of suboptimal platelet function is multifactorial. Platelets do not function well if there are too many or too few platelets; also the platelets can be present in the appropriate ...